SCHEMBL5565293

SCHEMBL5565293

CN[C@@H](C)C(O)C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.36
CA14 Q9ULX7 1/20 0.36
DGAT1 O75907 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CYP2D6 P10635 1/20 0.35
KMT2A Q03164 3/20 0.32
LMNA P02545 1/20 0.32
NOS1 P29475 2/20 0.31
NOS3 P29474 1/20 0.31
NOS2 P35228 1/20 0.31
MEN1 O00255 2/20 0.31
GAA P10253 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
TSHR P16473 1/20 0.30
HSD17B10 Q99714 1/20 0.30
CTSS P25774 1/20 0.30
CTSK P43235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5568407 0.81 CYP2D6 (0.45) CA12CA14DGAT1CA1CA2
SCHEMBL14574457 0.79 SMN1; SMN2 (0.41) CA12CA14CA1CA2CYP2D6
SCHEMBL14574444 0.79 SMN1; SMN2 (0.41) CA12CA14CA1CA2CYP2D6
SCHEMBL8028869 0.78 HTT (0.40) CA12CA14DGAT1CA1CA2
SCHEMBL19407016 0.78 HTT (0.40) CA12CA14DGAT1CA1CA2
SCHEMBL8030378 0.78 HTT (0.40) CA12CA14DGAT1CA1CA2
SCHEMBL1845280 0.78 HTT (0.40) CA12CA14DGAT1CA1CA2
SCHEMBL3728417 0.77 CA12 (0.42) CA12CA14DGAT1CA1CA2
SCHEMBL3725616 0.77 CA12 (0.42) CA12CA14DGAT1CA1CA2
SCHEMBL3725618 0.77 CA12 (0.42) CA12CA14DGAT1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312343-B2 N-benzyl-protected dialkyl acetal derivatives undergo desired aldol reaction with high diastereoselectivity using a Mukaiyama aldol reaction; intermediates in the synthesis of other products, including, e.g. Dolastatin 10 HOFFMANN-LA ROCHE INC. (US) 2007-12-25 US disclosed
EP-1756038-A1 SYNTHESIS OF AMINO-ALKOXY-HEPTANOIC ALKYL ESTER F.HOFFMANN-LA ROCHE AG (CH) 2007-02-28 EP disclosed
WO-2005118525-A1 SYNTHESIS OF AMINO-ALKOXY-HEPTANOIC ALKYL ESTER F.HOFFMANN-LA ROCHE AG (CH) 2005-12-15 WO disclosed
US-20050272665-A1 Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters F. HOFFMANN-LA ROCHE AG (CH) 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272665-A1 Synthesis of alpha-amino-beta-alkoxy-carboxylic acid esters ALDH7A1, BCAT1, BCAT2 CA12 1124/4885CA14 812/4885DGAT1 2522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.